Results from a Phase 1/2 trial of BB2603, a terbinafine-based topical nano-formulation, in onychomycosis and tinea pedis. Fuhr R, Cook D, Ridden J, Nield K, et al. Mycoses 2022;65:661-669.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fuhr R, Cook D, Ridden J, Nield K, et al. Results from a Phase 1/2 trial of BB2603, a terbinafine-based topical nano-formulation, in onychomycosis and tinea pedis. Mycoses 2022;65:661-669.
PMID: 35466481